Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Moderna, Inc. has announced plans to cut more than 800 jobs this year as part of a strategy to manage its cash flow amid ongoing financial challenges. The company is facing significant pressure to reduce costs following a decline in demand for its COVID-19 vaccine. This workforce reduction is part of a broader effort to streamline operations and ensure the company's long-term sustainability. The layoffs are expected to take place throughout the year as Moderna navigates its financial landscape.
Moderna, Inc. has announced plans to lay off 10% of its workforce as it prepares for its upcoming Q2 report. This decision reflects the company's ongoing adjustments in response to market conditions and operational needs. While the specific number of employees affected has not been disclosed, the layoffs are part of a broader strategy to streamline operations and enhance financial performance. The company is navigating a challenging environment, and these workforce reductions are aimed at positioning Moderna for future success.
Moderna, Inc. is cutting 10,000 jobs as part of a significant workforce reduction due to the erosion of its business. This decision reflects the company's response to changing market conditions and a decline in demand for its products. The layoffs are part of a broader restructuring effort aimed at stabilizing the company amid financial challenges. The exact locations and departments affected by these layoffs have not been specified, but the scale of the cuts indicates a major shift in the company's operational strategy.
Moderna, Inc. has announced the layoff of approximately 300 employees as part of its efforts to streamline operations and avoid further job cuts. The CEO emphasized that the company made 'every effort' to prevent these layoffs, indicating a challenging environment for the vaccine maker. This decision reflects the ongoing adjustments within the company as it navigates the post-pandemic landscape. The layoffs are part of a broader strategy to ensure the company's sustainability and efficiency moving forward.
Moderna, Inc. has announced a layoff affecting 10% of its workforce, translating to approximately 300 employees. This decision comes as the company faces financial pressures due to a dwindling cash reserve. The layoffs are part of a broader strategy to manage costs and adapt to changing market conditions. Moderna's leadership has indicated that these cuts are necessary to ensure the company's long-term sustainability. The layoffs are effective immediately, reflecting the urgency of the company's financial situation.
Moderna, Inc. has announced a layoff affecting 10% of its workforce due to financial concerns as its cash reserves diminish. This decision translates to approximately 1,000 employees being laid off. The company is facing challenges that have prompted this workforce reduction, reflecting broader issues within the biotech sector. The layoffs are part of a strategic adjustment to ensure the company's financial stability moving forward.
Moderna, Inc. has announced significant job cuts affecting approximately 1,000 employees as part of a restructuring effort to address ongoing financial challenges. The layoffs are set to take place in Cambridge, Massachusetts, where the company is based. This decision comes amid a broader context of declining revenues and the need to streamline operations following the pandemic. Moderna's leadership has indicated that these cuts are necessary to ensure the company's long-term viability and focus on its core research and development initiatives. The layoffs reflect a shift in the company's strategy as it navigates a post-pandemic landscape and seeks to adapt to changing market conditions.
Moderna, Inc., based in Massachusetts, has announced plans to lay off 10% of its workforce. This decision reflects the company's ongoing adjustments in response to market conditions and operational needs. While specific details regarding the timeline for these layoffs have not been disclosed, the announcement indicates a significant restructuring effort within the organization. The company aims to streamline operations and focus on its core objectives amidst changing industry dynamics.
No one has shared a story from Moderna, Inc. yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.